Lexicon Pharmaceuticals (LXRX) Profit After Tax (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Profit After Tax of -$1.0 million for Q1 2026, up 95.88% year-over-year from -$532478.0 in Q1 2025, and up 93.28% quarter-over-quarter from -$15.5 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Profit After Tax (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Profit After Tax data on file, last reported at -$1.0 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$1.0 million, up 95.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$26.1 million (up 85.28% YoY), and the FY2025 annual result was -$50.3 million, up 74.88% from the prior year.
- Profit After Tax improved to -$1.0 million in Q1 2026 per LXRX's latest filing, from -$15.5 million in the prior quarter.
- Over five years, Profit After Tax peaked at $3.3 million in Q2 2025 and troughed at -$64.8 million in Q3 2024.
- A 5-year average of -$31.2 million and a median of -$30.5 million in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2025: Profit After Tax sank 116.04% in 2023, then jumped 106.09% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$30.5 million in 2022, then plunged by 63.17% to -$49.8 million in 2023, then soared by 32.14% to -$33.8 million in 2024, then jumped by 54.01% to -$15.5 million in 2025, then jumped by 93.28% to -$1.0 million in 2026.
- Business Quant data shows LXRX's Profit After Tax at -$1.0 million in Q1 2026, -$15.5 million in Q4 2025, and -$12.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | -1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.04 Mn |
| Dec 31, 2025 | -15.53 Mn |
| Sep 30, 2025 | -12.77 Mn |
| Jun 30, 2025 | 3.25 Mn |
| Mar 31, 2025 | -25.30 Mn |
| Dec 31, 2024 | -33.77 Mn |
| Sep 30, 2024 | -64.81 Mn |
| Jun 30, 2024 | -53.43 Mn |
| Mar 31, 2024 | -48.40 Mn |
| Dec 31, 2023 | -49.76 Mn |
| Sep 30, 2023 | -50.53 Mn |
| Jun 30, 2023 | -44.90 Mn |
| Mar 31, 2023 | -31.93 Mn |
| Dec 31, 2022 | -30.49 Mn |
| Sep 30, 2022 | -23.39 Mn |
| Jun 30, 2022 | -24.59 Mn |
| Mar 31, 2022 | -23.48 Mn |
| Dec 31, 2021 | -25.61 Mn |
| Sep 30, 2021 | -23.12 Mn |
| Dec 31, 2020 | -5.50 Mn |